Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.49 |
| ▸ | MAPT | P10636 | 4/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | GSK3B | P49841 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | STAT3 | P40763 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5099651 | 0.81 | GSK3B (0.70) | SMN1; SMN2MAPTPKMGSK3BCYP1A2 | |
| SCHEMBL2402713 | 0.68 | GSK3B (0.76) | MAPTGSK3BCYP3A4MAPK1 | |
| SCHEMBL2404400 | 0.68 | GSK3B (0.79) | GSK3BCYP3A4 | |
| SCHEMBL9008399 | 0.68 | SMN1; SMN2 (0.67) | SMN1; SMN2MAPTLMNATSHRNPSR1 | |
| SCHEMBL9943968 | 0.67 | CYP1A2 (0.41) | GSK3BTSHRCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL2403904 | 0.66 | GSK3B (0.75) | GSK3BCYP2D6 | |
| SCHEMBL5041844 | 0.66 | GSK3B (0.78) | GSK3B | |
| SCHEMBL5105275 | 0.65 | GSK3B (0.61) | MAPTGSK3B | |
| SCHEMBL13722027 | 0.65 | GSK3B (0.55) | SMN1; SMN2GSK3BCYP1A2CYP2D6 | |
| SCHEMBL2403556 | 0.65 | GSK3B (0.70) | GSK3BLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120220591-A1 | PYRIMIDONE COMPOUNDS | SANOFI (FR) | 2012-08-30 | — | — | US | claimed |
| US-8940738-B2 | Pyrimidone compounds | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2015-01-27 | — | — | US | disclosed |
| US-8940738-B2 | Pyrimidone compounds | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2015-01-27 | — | — | US | disclosed |
| US-8940738-B2 | Pyrimidone compounds | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2015-01-27 | — | — | US | disclosed |
| US-20120220591-A1 | PYRIMIDONE COMPOUNDS | SANOFI (FR) | 2012-08-30 | — | — | US | disclosed |
| US-20120220591-A1 | PYRIMIDONE COMPOUNDS | SANOFI (FR) | 2012-08-30 | — | — | US | disclosed |
| EP-2464639-A1 | PYRIMIDONE DERIVATIVES USED AS TAU PROTEIN KINASE 1 INHIBITORS | Mitsubishi Tanabe Pharma Corporation (JP) | 2012-06-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120220591-A1 | PYRIMIDONE COMPOUNDS | MAPT, PRNP, PSEN1 | SMN1; SMN2 146/4885MAPT 1/4885PKM 187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.